Mallinckrodt initiates rolling submission for terlipressin NDA

With the submission of its clinical data package, UK biopharma, Mallinckrodt, has initiated the rolling submission of a New Drug Application (NDA) to US regulators for terlipressin, an investigational agent being investigated for the treatment of hepatorenal syndrome type 1 (HRS-1).

A rolling submission allows the company to submit portions of the regulatory application to the FDA as they are completed. The company expects to complete the submission of the NDA in the coming months.

If approved, terlipressin would be the first and only FDA-approved treatment option in the US for patients with HRS-1, an acute and life-threatening syndrome involving acute kidney failure in people with cirrhosis.

The NDA is based, in part, on results from the Phase 3 CONFIRM trial, which was the largest-ever prospective study conducted in patients with HRS-1, and the culmination of a sustained, 17-year effort to develop terlipressin for potential use in the US and Canada.

The trial met its primary endpoint of Verified HRS Reversal, defined as renal function improvement, avoidance of dialysis and short-term survival.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...

New class of precision medicine strips cancer of its DNA defences

A new precision medicine targeting cancer’s ability to repair its DNA has shown promising results in the first clinical trial of the drug class. The...

Tonix & Southern Research expand COVID-19 vaccine collaboration to include T cell study

New York biopharma, Tonix Pharmaceuticals, has expanded its strategic collaboration with Southern Research to include a study of T cell immune responses to SARS-CoV-2...

Related news

Avalon GloboCare & BOKU to advance intranasal & oral COVID-19 vaccine candidate

Avalon GloboCare, a New Jersey-based clinical-stage global developer of cell-based technologies and therapeutics, has partnered with the University of Natural Resources and Life Sciences...

Sanofi & Translate Bio expand collaboration to develop mRNA vaccines

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, are expanding their existing 2018...

Sarepta & Codiak to research, develop exosome-based therapeutics

Precision medicine specialist, Sarepta Therapeutics, and Codiak BioSciences, a company at the forefront of advancing engineered exosomes as a new class of biologic medicines,...

Gilead acquires equity interest in pioneering immunotherapy company

Gilead Sciences is acquiring a 49.9% equity interest in Pionyr Immunotherapeutics, a privately held San Fran company developing first-in-class cancer immunotherapies. The acquisition – for...